Skip to content


Nucala (mepolizumab) is an antibody pharmaceutical. Mepolizumab was first approved as Nucala on 2015-11-04. It is used to treat asthma in the USA. It has been approved in Europe to treat asthma. The pharmaceutical is active against interleukin-5.
Trade Name Nucala
Common Name Mepolizumab
Indication asthma
Drug Class Monoclonal antibodies: humanized, immunomodulating
Get full access now